Skip to main content
Caplight Logo









Plexium

Plexium

Private
San Diego, CaliforniaHealthcare & Life Scienceshttps://plexium.com/

Last Round

VC Round

Aug 25, 2025

Total Funding Raised

$165.1M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Plexium is a biotechnology company that develops targeted protein degradation therapeutics for the treatment of cancer and other serious diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

targeted protein degradationmolecular glueTPDdrug discovery platformprotein degraderbiotechundruggable targetsbiobuckstherapeutic candidatessmall molecule inhibitorsproteomicsdrug developmentoncologyneurologybiopharma

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Plexium Comparables

Compare Plexium with similar companies based on industry and business-model similarity.

Plexium comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Proxygen
93%
Amphista Therapeutics
90%
Ambagon Therapeutics
90%

Plexium Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundAug 25, 2025
VC RoundAug 25, 2024
Series BFeb 23, 2022
Series A ExtensionJan 21, 2021
Series AOct 17, 2019
Seed
Feb 1, 2018

Key People

Founding team and executive leadership

Serge Messerlian

Chief Executive Officer

Executive Team

Plexium Investors

Notable investors and investment history

Plexium investors
InvestorRounds
The Column GroupSeries B, Series A, Series A Extension
Surveyor CapitalSeries B
SoftBank Investment AdvisersSeries B
RA Capital ManagementSeries B
TCG CrossoverSeries B
A. M. Pappas & AssociatesSeries B
DCVC BioSeries A Extension, Series B, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 21, 2026

    Monthly visitors grew 73% MoM.

  • Apr 28, 2025

    Developing selective monovalent degrader programs targeting SMARCA2, IKZF2, and CDK2.

Plexium Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Plexium Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Plexium's valuation, stock price, and market status.

Firmographic Details

HeadquartersSan Diego, California
Employee Range30
Year Founded2017
Last FundingAug 25, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?